News & Updates

The COVID-19 pandemic has evidently affected the care and well-being of cancer patients, particularly those with advanced stages, reveals a recent study.

Individuals with long-term metabolic syndrome are at increased risk of developing gastrointestinal cancer overall, including colorectal and pancreatic cancers and hepatocellular carcinoma, with the risk increase independent of genetic predisposition, a study has found.

Local failure (LF) is more likely to occur in colorectal cancer (CRC) metastases treated with stereotactic ablative radiotherapy (SABR) if originating from right-sided primary CRC compared with left-sided, a study has found. In addition, LF rates are highest with liver metastases than other metastatic sites.

High-risk individuals who develop neoplastic progression to pancreatic cancer or high-grade dysplasia can present at an advanced stage despite showing no lesions during prior imaging surveillance evaluations, a new study has found.

Dietary intake of alpha linolenic acid (ALA) appears to reduce the risk of mortality from all causes, cardiovascular disease (CVD), and coronary heart disease (CHD) but may slightly increase the risk of cancer mortality, according to a systematic review and meta-analysis. Moreover, an association exists between higher blood levels of ALA and a lower risk of all-cause and CHD mortality.

In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression ≥1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.